Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

NexBio Reports Positive Data from Test of Biologic Flu Drug

publication date: Aug 30, 2011
View a Printer Friendly version of this page, allowing you to print the page.
NexBio, a San Diego biotech startup, has released positive data from a Phase II trial of a novel biologic that aims to both treat and prevent infection by all flu strains. The drug works by inhibiting entry of the virus into cells. NexBio was formed by a China husband-wife team who did their early academic work in China, and then moved to the US to earn biology PhDs. NexBio has been in the news recently because the FBI conducted a very public raid on the company’s offices, though neither the FBI nor the company has explained the object of the raid. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China